SCREENING

We have worked with BioFocus DPI, Ltd., a Charles River Laboratories subsidiary and a major Clinical Research Organization (CRO), for the virtual screening, assay development and optimization, compound selection and screening, and active-to-hit work to support hit identification of inhibitors of Fyn kinase.

​Read more...

SCIENTIFIC COMMUNITY VALIDATION
​
​We have received advice and counsel from a significant potential commercial partner about the design of the screening process so that we may customize a drug that will have maximum appeal in market distribution.

Read more...